NCT03810807 2025-12-23
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
26 trialsNCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT00728390 2024-04-22
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Pfizer
Phase 1 Completed
NCT04511533 2024-04-05
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
Pfizer
Phase 4 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT01000025 2023-08-22
PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01920061 2022-09-13
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Phase 1 Completed
NCT01520870 2021-07-06
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT01728233 2021-05-14
HER-Uro01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT00768664 2021-02-09
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Pfizer
Phase 2 Completed
NCT00548093 2019-05-21
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Pfizer
Phase 2 Completed
NCT01465802 2019-01-09
ARCHER 1042
Pfizer
Phase 2 Completed
NCT00818441 2019-01-08
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Phase 2 Completed
NCT01112527 2018-08-16
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT00728468 2017-08-02
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Pfizer
Phase 1 Completed
NCT01858389 2017-07-18
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT01360554 2017-05-24
ARCHER 1009
Pfizer
Phase 3 Completed
NCT01737008 2016-06-13
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto
Phase 1 Completed
NCT01152853 2015-11-20
PF299804-AGC
Seoul National University Hospital
Phase 2 Completed
NCT01121575 2015-10-28
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Pfizer
Phase 1 Completed
NCT00769067 2015-10-07
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Pfizer
Phase 2 Completed
NCT01116843 2015-07-10
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
University Health Network, Toronto
Phase 1/2 Completed
NCT01484847 2015-07-10
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
University Health Network, Toronto
Phase NA Completed
NCT01449201 2014-09-30
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Yonsei University
Phase 2 Completed
NCT00783328 2011-06-27
A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors
Pfizer
Phase 1 Completed